On Wednesday, Following Stocks were among the “Top 100 Losers” of U.S. Stock Market: EnLink Midstream Partners, LP (NYSE:ENLK), bluebird bio, Inc. (NASDAQ:BLUE), Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH), Integrated Device Technology, Inc. (NASDAQ:IDTI)
EnLink Midstream Partners, LP (NYSE:ENLK), with shares declined -8.99%, closed at $24.50, hitting new 52-week low of $23.84.
bluebird bio, Inc. (NASDAQ:BLUE), with shares dropped -8.88%, settled at $110.42.
Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH), with shares dipped -9.21%, and closed at $4.34.
Integrated Device Technology, Inc. (NASDAQ:IDTI), plummeted -9.10%, and closed at $19.54.
Latest NEWS regarding these Stocks are depicted underneath:
EnLink Midstream Partners, LP (NYSE:ENLK)
EnLink Midstream Partners, LP (ENLK), declared the pricing of an underwritten public offering of 22,800,000 ordinary units representing limited partner interests in the Partnership owned by a partner of Devon Energy Corporation.
The offering was priced at $25.71 per ordinary unit. Devon has also granted the underwriters a 30-day option to purchase up to 3,420,000 additional ordinary units. The Partnership will not receive any proceeds from the offering of ordinary units. The total number of outstanding ordinary units of the Partnership will remain unchanged. The offering is predictable to close on or about March 30, 2015, subject to customary closing conditions.
Morgan Stanley is acting as representative and joint book-running manager for the offering. In addition, BofA Merrill Lynch, Barclays, Wells Fargo Securities, J.P. Morgan, UBS Investment Bank, Citigroup, Credit Suisse, Deutsche Bank Securities, Goldman, Sachs & Co., RBC Capital Markets, Jefferies and Raymond James are acting as joint book-running managers. Baird and Oppenheimer & Co. are acting as co-managers for the offering. When accessible, copies of the preliminary prospectus supplement, the prospectus supplement and the accompanying base prospectus regarding the offering may be obtained from Morgan Stanley, Attn: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014.
Enlink Midstream Partners, LP, through its subsidiary, EnLink Midstream Operating, LP, provides midstream energy services. The company provides gathering, transmission, processing, fractionation, brine, and marketing services to producers of natural gas, natural gas liquids (NGL), crude oil, and condensate.
bluebird bio, Inc. (NASDAQ:BLUE)
Members of the administration team of bluebird bio, Inc. (BLUE), presented at the Alliance for Regenerative Medicine’s 3rd Annual Regen Med Investor Day on Wednesday, March 25, 2015 at the Metropolitan Club in New York City. bluebird bio also took part in a panel titled, “Adoptive T-Cell Therapies: Considering Key Forthcoming Clinical & Commercial Milestones” that day.
bluebird bio, Inc., a clinical-stage biotechnology corporation, focuses on developing transformative gene therapies for severe genetic and rare diseases. Its advanced product candidate is Lenti-D, which is in phase II/III clinical studies for the treatment of childhood cerebral adrenoleukodystrophy, a rare, hereditary neurological disorder affecting young boys; and LentiGlobin that is in phase I/II clinical studies for the treatment of beta-thalassemia major and severe sickle cell disease (SCD) in France, in addition to a phase I study in the United States for the treatment of severe SCD.
Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH)
Formerly on March 19, Anthera Pharmaceuticals, Inc. (ANTH), declared it has received an award from Cystic Fibrosis Foundation Therapeutics Inc. of up to $3 million to support the manufacturing and clinical development of Anthera’s novel pancreatic enzyme replacement therapy, Sollpura™ (liprotamase). Cystic Fibrosis Foundation Therapeutics is a non-profit associate of the Cystic Fibrosis Foundation.
Anthera plans to start a Phase 3 registration trial for liprotamase (SOLUTION), in the third quarter of 2015. If the results are positive, Anthera will complete clinical and regulatory activities needed to file a New Drug Application with the U.S. Food and Drug Administration.
“We are excited about the possibility of offering an alternative pancreatic enzyme therapy to people with CF,” said Paul F. Truex, Anthera’s President and Chief Executive Officer. “Support from Cystic Fibrosis Foundation Therapeutics speaks to the importance of developing liprotamase and the organization’s extensive clinical trials network will be indispensable as we advance this therapy.”
The corporation was founded in 2004 and is headquartered in Hayward, California. Anthera Pharmaceuticals, Inc., a biopharmaceutical corporation, focuses on developing and commercializing products to treat diseases associated with inflammation and autoimmune diseases. It is developing blisibimod, a Phase III product candidate that targets elevated levels of B-cell activating factor associated with various B-cell mediated autoimmune diseases, counting systemic lupus erythematosus, IgA nephropathy, lupus nephritis, multiple myeloma, vasculitis, idiopathic thrombocytopenia purpura, and others.
Integrated Device Technology, Inc. (NASDAQ:IDTI)
Integrated Device Technology, Inc. (IDTI), declared it has named David Chen as vice president of sales for China, Taiwan, India, and Southeast Asia, effective March 16. Chen will be based in IDT’s Shanghai office.
Chen brings more than 25 years of experience in the semiconductor industry, most at Intersil, where he worked for 13 years and left with the title of China country manager. Preceding to Intersil, Chen spent six years with Texas Instruments as sales director for TI’s wireless business, and nine years with NXP Semiconductors (formerly Philips Semiconductors) as applications engineering manager for MCU products for wireline and wireless OEM customers. He has a BSEE degree from Shanghai Jiao Tong University.
Integrated Device Technology, Inc. designs, develops, manufactures, and markets a range of mixed signal semiconductor solutions for the communications, computing, and consumer industries worldwide. It operates in two segments, Communications, and Computing and Consumer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
